Eli Lilly and Company (NYSE:LLY) Shares Acquired by Quent Capital LLC

Quent Capital LLC raised its position in Eli Lilly and Company (NYSE:LLY) by 0.5% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,151 shares of the company’s stock after acquiring an additional 24 shares during the quarter. Quent Capital LLC’s holdings in Eli Lilly and Company were worth $4,559,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. J. W. Coons Advisors LLC boosted its stake in Eli Lilly and Company by 4.0% during the 4th quarter. J. W. Coons Advisors LLC now owns 2,324 shares of the company’s stock worth $1,355,000 after purchasing an additional 90 shares during the period. Morningstar Investment Services LLC raised its stake in Eli Lilly and Company by 81.9% during the 4th quarter. Morningstar Investment Services LLC now owns 3,167 shares of the company’s stock valued at $1,840,000 after acquiring an additional 1,426 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd lifted its position in Eli Lilly and Company by 7,350.0% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 74,500 shares of the company’s stock worth $43,428,000 after acquiring an additional 73,500 shares during the period. Wescott Financial Advisory Group LLC grew its stake in shares of Eli Lilly and Company by 2.6% in the 4th quarter. Wescott Financial Advisory Group LLC now owns 8,201 shares of the company’s stock valued at $4,781,000 after purchasing an additional 209 shares during the last quarter. Finally, Waterloo Capital L.P. increased its holdings in shares of Eli Lilly and Company by 159.4% in the fourth quarter. Waterloo Capital L.P. now owns 1,266 shares of the company’s stock valued at $738,000 after purchasing an additional 778 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Ratings Changes

LLY has been the subject of several recent analyst reports. Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. BMO Capital Markets lifted their price objective on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Jefferies Financial Group increased their target price on Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research note on Monday, June 24th. Berenberg Bank lifted their price target on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th. Finally, Wells Fargo & Company increased their price objective on Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research report on Friday, August 9th. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $977.35.

Insider Buying and Selling

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 93,593 shares of the stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $918.64, for a total transaction of $85,978,273.52. Following the transaction, the insider now owns 97,153,810 shares of the company’s stock, valued at $89,249,376,018.40. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Trading Up 0.2 %

Shares of NYSE:LLY traded up $1.61 during trading on Friday, reaching $887.16. The stock had a trading volume of 1,971,436 shares, compared to its average volume of 3,031,093. The business has a fifty day moving average price of $900.13 and a 200-day moving average price of $847.35. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. The stock has a market cap of $843.16 billion, a P/E ratio of 130.66, a PEG ratio of 2.78 and a beta of 0.42. Eli Lilly and Company has a fifty-two week low of $531.61 and a fifty-two week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The business had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. As a group, analysts anticipate that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.